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Abstract
The introduction of novel agents in the management of multiple myeloma and related plasma cell dyscrasias has changed our
treatment approaches and subsequently the outcome of patients. Due to current advances, the European Myeloma Network
updated the diagnostic and therapeutic recommendations for patients with Waldenström’s macroglobulinemia (WM), AL-
amyloidosis, monoclonal immunoglobulin deposition disease (MIDD), POEMS syndrome, and primary plasma cell
leukemia. For patients with WM, the combination of rituximab with chemotherapy remains the treatment cornerstone, while
the Bruton-tyrosine kinase inhibitor ibrutinib has been introduced and approved for relapsed/refractory disease. The
management of light chain amyloidosis depends on the presence and severity of heart disfunction. If present, intensiﬁcation
with an autologous stem cell transplantation (ASCT) is not recommended. Further aggregation of misfolded light chains
could be prevented by doxycycline or monoclonal antibodies targeting amyloid deposits. Initial treatment generally consists
of melphalan/dexamethasone or bortezomib-based regimens. For relapsing patients, one can consider proteasome inhibitors,
immunomodulatory agents, melphalan or daratumumab. Because intact or light-chain immunoglobulins are also the culprits
for MIDD, the small monoclonal plasma cells' clones should be treated and generally respond well to bortezomib-based
treatment. POEMS syndrome is a well-deﬁned clinical entity that can present as solitary bone lesions or disseminated
disease. Radiation therapy is used for patients with localized disease and result in long-lasting response. Systemic treatment
should be proposed to patients with disseminated disease, but regimens that can worsen a pre-existing polyneuropathy
should be avoided. PPCL is located at the other end of the spectrum of plasma cell disorders and is associated with an
aggressive disease course and poor prognosis. It requires an imminent, multi-phase and novel agents-based therapy,
including induction, ASCT, consolidation and maintenance, with short treatment-free intervals. Patients not eligible for
transplant procedures require personalized, intensive therapeutic approach. Allogeneic stem cell transplantation can be used
in selected patients.
Introduction
Plasma cell dyscrasias (PCD) other than multiple myeloma
(MM) can present in different clinical forms, ranging from
indolent disease with small clones of monoclonal cells that
produce a monoclonal protein which can either be innocent
or causes devastating complications to highly aggressive
forms characterized by malignant plasma cells that evade
the bone marrow (BM) resulting in overt plasma cell leu-
kemia. Waldenström’s macroglobulinemia (WM), primary
systemic AL-amyloidosis, monoclonal immunoglobulin
deposition disease (MIDD), POEMS-syndrome, and pri-
mary plasma cell leukemia (PPCL) all belong to the
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spectrum of PCD. Due to the rarity of these disorders most
available results regarding potential therapeutic strategies
are based on phase 2 studies, case series, and registry data.
The aim of this paper of the European Myeloma Network
(EMN) is to provide useful recommendations on diagnosis
and management of these entities.
Methodology
An interdisciplinary panel of PCD experts on behalf of the
EMN reviewed all published randomized and phase II
clinical trials, guidelines, meta-analyses, systematic
reviews, observational studies, case series, case reports and
published registry data on diagnosis and management of
these disorders. The research was performed in PubMed and
ISI until 28th February 2018. The Grading of Recommen-
dations Assessment Development and Evaluation (GRADE)
system was used for the grading of the recommendations
(Supplementary Table 1). In the case of limited sufﬁcient
data an expert consensus was used to develop recommen-
dations. The paper was circulated among the panel mem-
bers, initial discussion took place at the 9th EMN Trialist
meeting (Baveno, Italy, 25–26 September 2016) and the
recommendations were approved by the panel members and
the participants of the subsequent Baveno meeting (24–25
September 2017). Subsequently, the manuscript underwent
two-round revisions between the panel members.
Waldenstrom’s macroglobulinemia
Diagnosis
WM is characterized by clonal lymphoplasmacytic cell BM
inﬁltration and the presence of monoclonal IgM paraprotein
[1]. According to the Second International Workshop
for WM, diagnostic clinic-pathologic criteria have
been established for WM diagnosis based on BM results
combined with immunophenotyping studies [2]. Especially
immunophenotyping is of great value; the proﬁle for lym-
phoplasmacytic cells should include the expression of
B-cells antigens CD19, CD20, CD22, CD25, CD79,
and CD112. Approximately 15% of the patients express
CD5 as well, while quite common is the expression of
CD10 and CD23. Immunophenotype should also include
plasma cell component and expression of CD38, CD138
and light chain restriction needs to be encountered.
Expression needs to be encountered [3]. Patients with
≥10% lymphoplasmacytic cell inﬁltration are considered
as WM, otherwise as IgM-MGUS. Criteria for treatment
initiation include cytopenias, constitutional symptoms, orga-
nomegaly, hyperviscosity, cryoglobulinemia, amyloidosis,
hemolytic anemia, cold agglutinin disease, and peripheral
neuropathy (Table 1) [2, 4].
Recommendations
To diagnose patients with WM perform BM biopsy and
immunophenotyping studies. To evaluate tumor burden and
treatment response perform serum immunoelectrophoresis,
immunoglobulins measurement, CT scans involving pelvis,
abdomen, chest and cervical area, cold agglutin, and cryo-
globulins measurements.
Treatment
WM is a rare disease; therefore, treatment options have
been adopted mainly from phase 2 studies. Rituximab is an
anti-CD20 monoclonal antibody which remains standard of
care for most patients and is used alone or in combinations.
When used as monotherapy duration of response is
8–11 months in both untreated and relapsed/refractory
patients [5, 6]. Although it is well tolerated, approximately
50% of patients may experience an IgM ﬂare (deﬁned as
≥25% increase above baseline serum IgM level), therefore
in patients with high IgM levels (greater than 5000 mg/dl),
it should either be combined with plasma exchange or
avoided until the IgM monoclonal protein has decreased [7].
Ofatumumab is a fully human anti-CD20 antibody targeting
another CD20 epitope. As monotherapy, overall response
rates (ORRs) reach 59%, therefore in rituximab-intolerant
patients, this may represent a potentially therapeutic option
[8]. Monoclonal antibodies are active and non-myelosup-
pressive, thus can be combined with chemotherapy when
Table 1 Indication for treatment initiation in patients with
symptomatic WM
Clinical indications for treatment initiation
Recurrent fever, night sweats, weight loss, fatigue
Lymphadenopathy which is either symptomatic or bulky (≥5 cm in
maximum diameter)
Hyperviscosity
Symptomatic hepatomegaly and/or splenomegaly
Symptomatic organomegaly and/or organ or tissue inﬁltration
Peripheral neuropathy due to WM
Laboratory indications for treatment initiation
Symptomatic cryoglobulinemia
Cold agglutinin anemia
Immune hemolytic anemia and/or thrombocytopenia
Amyloidosis related to WM
Nephropathy related to WM
Hemoglobin ≤ 10 g/Dl
Platelet count < 100 × 109/L
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rapid control is required. The combination of dex-
amethasone, rituximab, and cyclophosphamide (DRC) was
evaluated in a prospective study of 72 untreated WM
patients with 83% ORR. The 2-year progression-free sur-
vival (PFS) was 67%. Median time to response was
4.1 months, suggesting that the combination is not appro-
priate for rapid disease control [9]. The combination of
rituximab with ﬂudarabine, with or without cyclopho-
sphamide (FCR), is very effective with a median PFS
exceeding 50 months [10–12]; however, due to the
increased risk of long-lasting cytopenias and secondary
primary malignancies (high grade lymphoma, MDS, AML),
it is not recommended as ﬁrst-line treatment except for
high-risk patients. Rituximab combined with bendamustine
showed 95% ORR with 69.5 months PFS and safer toxicity
proﬁle when compared to R-CHOP in a phase 3 trial of
indolent non-Hodgkin lymphoma (NHL), including WM
[13]. Similar ORR (83%), with median PFS of 13 months,
were achieved when administered in 30 WM relapsed/
refractory patients [14]. Efﬁcacy and toxicity of bortezomib,
dexamethasone, and rituximab (VDR) was evaluated in 59
newly diagnosed patients [15]. The results of this study
have been recently updated and the median PFS after 6
years of follow-up was 43 months and the overall survival
rate was 68%. Carﬁlzomib is associated with lower neuro-
toxicity in MM patients and was recently evaluated in
combination with rituximab and dexamethasone, mainly in
untreated WM patients [16]. The ORR was 87%, MYD88
or CXCR4 mutation status had no impact, and no grade ≥ 3
neuropathy was observed. However, carﬁlzomib is currently
available only in the United States (US) as an off-label
indication for WM.
The role of maintenance still remains unclear. Limited
data are available; although rituximab seemed to improve
PFS and OS, it resulted in pronounced immunosuppression,
therefore it is not recommended in everyday clinical prac-
tice [17].
Autologous stem cell transplantation (ASCT) remains an
option as salvage therapy in WM, particularly for younger
patients with multiple relapses or primary refractory dis-
ease; however, data on the role of ASCT in the primary
refractory setting and on allogeneic transplantation for these
patients are very limited [18].
In a phase 1/2 study with 17 previously untreated
patients, lenalidomide maximum tolerated dose was deﬁned
as 15 mg and provided 29% ORR, with median time to
progression of 16 months and 5-year OS of 91% [19]. The
toxicity was mainly hematologic. The combination of
pomalidomide, dexamethasone, and rituximab was also
explored in treatment-naive WM patients in a dose-
escalating phase 1 study [20]: among seven enrolled
patients, three (43%) achieved major response. The long-
term results of a phase 2 trial with everolimus in 60
relapsed/refractory patients showed 50% PR and median
PFS 21 months [21]. Toxicity was quite pronounced
including cytopenias and pulmonary toxicity. In a phase 1/
2 study of everolimus combined with rituximab, with or
without bortezomib, in 46 patients showed a response rate
of 89% and median PFS of 21 months [21]. Everolimus is
currently available only in the US as an off-label indication.
Ibrutinib, a BTK inhibitor, is very effective in high-risk
patients with chronic lymphocytic leukemia (CLL) and
mantle-cell lymphoma. The results of a prospective study of
ibrutinib in 63 patients with WM who had received at least
1 previous line of treatment were recently reported [22].
Median time to at least minor response was 4 weeks. After a
median follow-up of 47.5 months the ORR was 91%, the
median PFS has not yet been reached and the 2-year OS
was 95%. The main adverse events were neutropenia,
thrombocytopenia, post-procedural bleeding, and atrial
ﬁbrillation [22, 23]. Most patients were able to continue
ibrutinib after cardiologic intervention and/or dose reduc-
tion [24]. In patients with preexisting atrial ﬁbrillation that
require anticoagulants, alternative treatment options should
be considered. MYD88 and CXCR4 mutations might have
an impact on ORRs and major responses to ibrutinib: WM
patients with wild-type MYD88 had lower ORR rates and
shorter duration of response [25]. CXCR4 mutations are
related to lower ORRs as well as delayed responses [25].
Testing for MYD88 is recommended for ibrutinib candi-
dates. The EMN-panel agreed that MYD88 and CXCR4
mutation status should be further investigated in order to
clarify its impact on treatment outcome and whether any
therapeutic decisions can be based on the mutational status.
Ibrutinib was also assessed in heavily pretreated and
refractory to rituximab patients with an ORR of 90%, an
estimated 18-month PFS of 86% and estimated 18-month
OS of 97%. Although the number of patients included in
this study was quite small (31) it seems that ibrutinib is
extremely effective even in this heavily pretreated popula-
tion [26]. Novel BTK inhibitors (CC-292, ONO-4059,
ACP-196, and BGB-3111) are in clinical development and
may offer potential future options.
The aim of ﬁrst-line treatment is therefore to achieve
high response rates with prolonged PFS (Tables 2A and
2B). The EMN-panel also agreed that clinical trials with
chemotherapy-free combinations, with new compounds
alone and/or with anti-CD20 antibodies should be per-
formed. Especially trials in the frontline setting including
ibrutinib and BCR inhibitors are needed to assess the efﬁ-
cacy and tolerability. Furthermore, the panel agreed that the
role of BCR inhibitors with other compounds as well as
with proteasome inhibitors to overcome drug-resistance
involved in the two key pathways affected by
MYD88 should be further explored in the relapsed/refrac-
tory setting. Obinutuzumab, a novel anti-CD20 monoclonal
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell. . . 1885
antibody which has shown efﬁcacy in CLL and follicular
lymphoma, could be a potential therapeutic agent. CXCR4
antagonists such as plerixafor or ulocuplumab are currently
under development and may offer options to extend the
activity affected by the CXCR4 mutation.
Recommendations
Rituximab monotherapy can be considered for WM patients
with immunologic disorders secondary to WM or for frail
patients who are less likely to tolerate chemotherapy (1B).
Rituximab should be avoided or withheld, or preemptive
plasma exchange should be performed in patients with high
IgM levels due to risk of IgM ﬂare.
Chemoimmunotherapy combinations with rituximab,
cyclophosphamide, and dexamethasone (1B), benda-R
(1B), or bortezomib, rituximab, and dexamethasone (1B)
provide durable responses with tolerable toxicity and are
recommended in most patients. For high-risk patients or
patients with hyperviscosity where rapid control of the
disease is required bortezomib, nucleoside analogues-based
regimens or bendamustin-based regimens should be pre-
ferred, while bortezomib should be avoided in patients with
paraprotein-related neuropathy (1B).
For elderly patients, DRC or oral ﬂudarabine should be
treatments of choice (1A). Ibrutinib represents an effective
option for both treatment-naive and relapsing patients (1B)
but is not recommended for patients with MYD88WT dis-
ease (1A). In the relapsed/refractory setting and in patients
intolerant to rituximab ofatumumab can be considered (1B).
ASCT remains an option for high-risk patients, however
the data available are very limited (1B). Everolimus should
be considered only for non-responders after multiple lines
of therapy (1B). Treatment with any of the available ther-
apeutic agents listed for untreated patients can be con-
sidered for previously treated patients requiring therapy
(Table 2C).
IMiDs and allogeneic SCT should be used only in the
context of clinical trials (1C). Enrollment in clinical trials is
highly recommended for patients with WM.
Table 2A Therapeutic algorithm
for patients with newly
diagnosed (ND), symptomatic
WM
Clinical condition Treatment recommendation
Cytopenias and/or organomegaly DRC, Bendamustine-Rituximab (R) or
Bortezomib-R
Comorbidities and cytopenias Rituximab, DRC
High M-protein, transplant candidate DRC, Bortezomib-R or Bendamustine-R
High M-protein, non-transplant candidate DRC, Bendamustine-R, Bortezomib-R
Older age, slow progression, poor PS, candidate for
oral therapy
DRC, Oral ﬂudarabine
Symptomatic hyperviscosity, cryoglobulinemia or
cold agglutinemia
Bortezomib followed by Bortezomib-R,
Bendamustine-R, FCR
Paraprotein-related neuropathy R alone, DRC, FR, Bendamustine-R
DRC dexamethasone, rituximab, cyclophosphamide, FCR ﬂudarabine, cyclophosphamide, rituximab,
R rituximab Bortezomib is not recommended for patients with neuropathy
Table 2B Recommendations on management of ND, symptomatic WM patients
Rituximab monotherapy Consider for WM patients with immunologic disorders related to WM, or for frail patients unlikely to tolerate
chemotherapy. Avoid in patients with high IgM levels
DRC Active, safe combination, even for elderly patients
Bortezomib-based regimens Consider for patients with high IgM levels, symptomatic hyperviscosity, cryoglobulinemia or cold agglutinemia,
amyloidosis, and renal impairment or in young patients to avoid myelotoxic agents. Consider subcutaneous use
and weekly administration to reduce neurotoxicity.
Bendamustine-Rituximab Well tolerated even in elderly patients. In elderly patients and those with renal impairment, consider dose
adjustment of bendamustine. Four cycles seem to be adequate to achieve response.
Carﬁlzomib-based regimens Neuropathy-sparing option for proteasome-inhibitor based therapy. Consider possible cardiotoxicity. The optimal
dose and schedule of carﬁlzomib are under investigation. Currently limited data
Ibrutinib Consider as primary for symptomatic patients not candidates for chemoimmunotherapy. Serum IgM might increase
and hemoglobin might decrease, if ibrutinib is stopped and should not be considered as treatment failure
Plasmapheresis Consider immediately for patients with symptomatic hyperviscosity or prevent ﬂare in patients with high IgM level
(typically >4000 mg/dL) before rituximab administration. Always combine with chemoimmunotherapy or targeted
therapy
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AL amyloidosis
Diagnosis
Light chain (AL)-amyloidosis is caused by a usually small
plasma cell clone producing a misfolded light chain protein
that forms ﬁbrillar deposits in tissues. Although several
organs might be involved survival is mainly determined by
the extent of heart involvement [27]. Although survival has
increased in the past decade, only minor improvement is
observed in early mortality as a result of advanced cardiac
involvement and approximately 30% of the patients die
within the ﬁrst year from diagnosis [28]. Diagnosis requires
proven amyloid deposits in a tissue biopsy. Abdominal fat
aspirate is very sensitive and represents a less invasive
technique [29]. Salivary gland biopsy is also easy to per-
form and identiﬁes approximately 60% of the patients with
negative abdominal fat [30]. However, to ensure diagnosis,
biopsy of the involved organ is recommended if feasible.
Imaging techniques are of important value in identifying
heart involvement. The echocardiographic features are dis-
tinctive, with thickening of the ventricular walls and inter-
ventricular and interatrial septa. Furthermore, amyloid
deposits give the characteristic “granular sparkling” to the
myocardial texture. Cardiac magnetic resonance imaging
shows global subendocardial late gadolinium enhancement.
The speciﬁc amyloid type needs to be identiﬁed in amyloid
deposits samples. Light microscopy immunohistochemistry
can classify almost 95% of the patients, but only in very
experienced centers [31]. Immunoelectron microscopy
achieves 100% speciﬁcity and can classify more than 99%
of patients [29]. Mass spectrometry-based proteomics
overcome the limitations of the above-mentioned techni-
ques and improve the diagnostic accuracy [32]. Gene
sequencing is necessary in order to rule out or conﬁrm
hereditary amyloidosis. Cardiac scintigraphy with bone
tracers distinguishes AL from transthyretin amyloidosis.
The identiﬁcation of the amyloidogenic light chains requires
immunoﬁxation of both serum and urine and FLCs mea-
surement [33].
Recommendations
The diagnosis requires proven amyloid deposits on tissue
biopsy. Abdominal fat aspirate is very sensitive; however,
when negative, salivary glands biopsy should be performed,
otherwise biopsy of the involved organ. Light microscopy,
immunohistochemistry, immunoelectron microscopy or
mass spectrometry is needed to type the amyloid. Imaging
techniques and cardiac biomarkers to evaluate cardiac
involvement are crucial. For renal involvement perform
24 h urine collection and urine immunoﬁxation. Perform an
abdomen CT scan or ultrasound if alkaline phosphatase is
elevated to evaluate liver involvement. The assessment of
the plasma cell clone and of the amyloidogenic light chain
requires BM biopsy or aspirate, serum immunoﬁxation and
FLCs measurement.
Treatment
ASCT represents an important treatment option in the
treatment of AL amyloidosis [34]. Cardiac biomarkers
play a signiﬁcant role in the assessment of eligibility for
ASCT. Troponin T levels > 0.06 ng/mL or NT-proBNP
levels > 5000 ng/L are associated with high transplant-
related mortality [34]. Hematologic response rates exceed
70% [35, 36]. Updated results from Boston showed an OS
of 7.6 years and approximately 55% of CR patients are
projected to be alive at 14 years, suggesting that a pro-
portion of patients achieving CR might be cured [36]. For
patients who fail to achieve CR, bortezomib can increase
CR rate to almost 60% [37]. Although ASCT is very
Table 2C Recommendation on management of previously treated WM patients
Ofatumumab Consider for patients intolerant to rituximab
Nucleoside analogues For ﬁt WM patients where other less toxic treatments have failed. For ASCT candidates: collect stem
cells before ﬂudarabine administration.
Ibrutinib Approved for symptomatic patients. Active. Should not be interrupted because this leads to
hemoglobin decrease and IgM increase. Primary choice for rituximab-refractory patients
Everolimus Considered for non-responders after multiple lines of other better-tolerated therapies. BM biopsies
help to clarify disease response or progression given the IgM discordance observed with this agent.
Immunomodulatory agents Consider only in the context of clinical trials
Autologous/allo-stem cell transplantation In selected WM cases, for high-risk WM patients. Not beneﬁcial for patients exposed to more than
3 lines of therapy or with chemotherapy refractory disease. Allo-SCT should be preferably done in
clinical trials.
Retreatment Treatment with any of the available therapeutic agents listed for symptomatic, untreated patients can
be considered for previously treated patients requiring therapy. May be considered if a response was
achieved for 2 or more years with the prior regimen. Patients progressing on ﬁrst-line ibrutinib should
not be retreated with ibrutinib.
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effective, the majority of the patients are not eligible
(Table 3).
For intermediate-risk patients standard treatment has
been oral melphalan/dexamethasone (MDex), BMDex or
VCD [38]. In recent updated data after a median follow-
up of 6 years, in patients receiving full-dose dex-
amethasone, the OS was 7.3 years. Hematologic response
rate was 76% [38]. 80% of the patients who achieved
CR with MDex are expected to be alive at 7 years [38].
These results are similar to those after ASCT. One of
the few randomized trials indeed compared ASCT and
MDex [39]: unfortunately, treatment related mortality
was substantial (24%) due to suboptimal eligibility criteria.
However, a landmark analysis excluding early deaths
demonstrated no survival advantage for one arm over
the other [39]. Further studies are required to deﬁne for
which group of patients ASCT demonstrates the most sig-
niﬁcant beneﬁt.
The availability of novel agents, especially bortezo-
mib, have created great expectations [40]: both large
retrospective series and prospective trials have proven
efﬁcacy and safety of bortezomib in AL-amyloidosis [41,
42]. Recently, two retrospective series showed sig-
niﬁcant hematologic responses (up to 90%) in newly
diagnosed patients receiving VCD [43, 44]. Following
these results, two retrospective matched case-control
studies compared bortezomib, dexamethasone, and
alkylating agents (BMDex and VCD) with MDex or
cyclophosphamide/thalidomide/dexamethasone (CTD).
The response rates were higher for the bortezomib
combinations-although not as high as previously repor-
ted; however, with no OS beneﬁt [45, 46]. A randomized
phase 3 study comparing MDex and BMDex has
completed recruitment (NCT01277016). The ﬁrst interim
analysis showed higher hematologic response rates with
BMDex however, further follow-up is needed to deter-
mine a potential survival beneﬁt [47]. Patients who fail
to achieve deep responses rapidly should be considered
for second-line treatment. Immunomodulatory drugs
(IMiDs) are mainly used in relapsed/refractory patients.
Moreover, lenalidomide and pomalidomide seem to
overcome resistance to bortezomib and alkylating agents
with hematologic response from 40 to 60% [48, 49].
IMiD combinations especially with alkylating agents can
achieve higher response rates, but toxicity and myelo-
suppression are of concern in these patients [50–52].
Lenalidomide dosing is according to eGFR and relevant
dose adjustments should be performed in patients with
proteinuria or renal impairment [53]. Ixazomib has been
investigated in a phase 1/2 trial in relapsed/refractory
patients with AL-amyloidosis, showing efﬁcacy parti-
cularly in bortezomib-naïve subjects [54]. A randomized
phase 3 trial comparing ixazomib with physician’s best
choice is still ongoing (NCT01659658). An alternative
option for relapsed/refractory patients is bendamustine.
A prospective trial showed 40–50% hematologic
response [55]. Bendamustine is effective especially in
WM-related AL. Daratumumab is well tolerated and
effective in heavily pretreated patients, with an overall
hematologic response rate of 76%, including CR in 36%
and very good partial response in 24%. Median time to
response was one month [56]. Carﬁlzomib showed good
efﬁcacy in a phase I/II study, with a 63% response rate,
but also important grade 3/4 cardiopulmonary toxicities
in 36% of patients [57]. Doxycycline was also shown to
promote amyloid ﬁbrils disruption in vitro and managed
to reduce the amyloid load in a transgenic mouse model
[58]. In a case/control study, the combination of dox-
ycycline with chemotherapy improved survival of
patients with stage II/IIIa [59].
CPHPC is a competitive inhibitor of serum amyloid
P component binding to amyloid ﬁbrils [60]. The ﬁrst
results of combined CPHPC and anti-serum amyloid P
component antibodies in humans were encouraging [61].
The ﬁrst phase 1/2 study of NEOD001, a monoclonal
antibody targeting amyloid deposits, showed a cardiac
response rate of 50%, and renal responses of 43% [62].
Therefore, a randomized, placebo-controlled phase 3 trial
comparing VCD with or without NEOD001 in patients with
AL-amyloidosis and heart involvement was designed and
completed accrual (NCT02312206); however, the results
showed no beneﬁt in terms of cardiac response and it was
very recently discontinued. The anti-LC monoclonal anti-
body 11-1F4 with speciﬁcity for an amyloid-related epitope
showed promising results in a phase 1 study inducing car-
diac and renal responses [63].
Table 3 Recommended supportives in patients with primary systemic
AL-amyloidosis
• Salt restriction and weight monitoring
• Diuretics-do not reduce the intravascular volume
• ACE inhibitors should be used at the lowest dose with caution due
to hypotension
• Elastic leotards for hypotension
• Midodrine for hypotension
• Pacemaker for patients with recurrent syncope due to arrhythmia/
ICD use remains controversial
• Amiodarone as antiarrhythmic-avoid digoxin
• Nutritional support
• Octreotide for diarrhea
• Gabapentin or pregabalin for neuropathic pain
• Organ transplant for patients with end-organ damage who achieve
CR.
• Left ventricular assist devices might be used as a bridge for
candidates for heart transplantation
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Supportive care is essential, especially for AL patients
with cardiac involvement in order to gain valuable time
until treatment achieves control of the disease. The main
recommendations are listed in Table 4.
The design of the therapeutic approach is based on
the staging of organ dysfunction and characterization of
the plasma cell clone. The cardiac biomarkers are
powerful predictors of survival. Therefore, they are
combined in an accurate staging system widely used for
management and stratiﬁcation in clinical trials or in every-
day clinic [64]. The difference between involved and
uninvolved FLCs (dFLC) is also prognostic and can
be integrated in the staging system based on cardiac
biomarkers [65]. Another study showed that patients
with BM plasma cell inﬁltration >10% have poor outcomes
[66] and seem to beneﬁt most from induction treatment
before ASCT [67]. Almost 80% of the patients eligible
for transplantation receive induction therapy with VCD,
while post ASCT bortezomib increases CR. In another
study patients with gain of chromosome 1q21 had
poorer outcomes when treated with MDex, whereas
t (11;14) was associated with inferior survival in patients
receiving VCD [68, 69]. High-risk patients do not
tolerate full dosed therapy; therefore, we recommend dose
and schedule adjustments. For young patients with
isolated heart involvement, heart transplantation followed
by ASCT may be considered. Furthermore, organ transplant
can be considered in patients who achieve CR but
have irreversible end-stage organ damage. The main
concern remains, however, disease recurrence. Table 4
summarizes tailored therapeutic approaches and recom-
mended therapeutic algorithms.
Recommendations
Due to the unique disease characteristics, the EMN-panel
recommends a risk-adapted approach, with dose adjust-
ments, schedule modiﬁcations and close monitoring of
hematologic and organ response. For low-risk per Mayo
stage, transplant-eligible patients consider induction with
VCD if BM inﬁltration is >10%, followed by ASCT/
HDM (1B). If the response achieved is less than CR
consider bortezomib after ASCT (1B). For intermediate-
risk patients consider MDex for those with neuropathy or t
(11;14), while for those with 1q21 or renal failure con-
sider VCD (1B). For patients with high dFLC BMDex
seems the most effective option (1B). For high-risk
patients bortezomib-based regimens and dose adjust-
ments are highly recommended (1B). In the relapsed/
refractory setting for PI-naive patients consider bortezo-
mib and ixazomib, while for PI refractory patients con-
sider IMiDs, daratumumab and bendamustine. For
alkylator-naive patients consider MDex or even ASCT if
the patient is eligible. Frontline treatment can be repeated
if it was beneﬁcial. Unfortunately, most available data
are based on retrospective case series. Therefore,
the enrollment of AL patients in clinical trials is highly
encouraged and patients should be referred to specialized
centers.
Table 4 Recommended treatment approaches for patients with AL-amyloidosis according to risk-adapted stratiﬁcation
Risk status FRONTLINE treatment Relapsed/refractory patients
Low risk, transplant eligible (Mayo stage 1 and
2, PS 0-2,
age < 65 years, eGFR > 50 ml/min/1.74 m2, NYHA
< 3, EF > 45%, sBP > 90 mm Hg (standing),
DLCO > 50%)
• MEL 200 mg/m2
• Consider induction with cyclophosphamide/
dexamethasone/bortezomib if bone marrow
inﬁltration is > 10%
• Consider bortezomib post ASCT if the response
is not CR
Repeat frontline treatment




Alkylator naïve: MDex, ASCT if
eligible
Intermediate risk (ineligible for ASCT,
stages 1-3a)
• For patients with t(11;14) MDex or BMDex
• For patients with neuropathy MDex
• For patients with 1q21 or renal failure VCD
Repeat frontline treatment




Alkylator naïve: MDex, ASCT if
eligible
High risk (stage 3b,
NYHA ≥ 3)
• Dose and schedule adjustments at lower doses
• Bortezomib-based combinations
Repeat frontline treatment




Alkylator naïve: MDex, ASCT if
eligible




Monoclonal immunoglobulin deposition disease (MIDD) is
a rare PCD characterized by the deposition of monotypic
immunoglobulin fragments along basement membranes in
the kidneys leading to subsequent proteinuria and renal
deterioration [69]. MIDD is a multi-systemic disease, with
almost always renal involvement [70–73], while cardiac,
hepatic, and neural deposits are less common [70, 71, 73,
74]. Diagnosis is based on the typical histological ﬁndings of
renal biopsy using immunoﬂuorescence (IF) and electron
microscopy [73, 75]. In the majority of MIDD patients,
small, indolent clones are found in the BM, that are
responsible for devastating complications and end-organ
damage [75].
Recommendations
Perform a renal biopsy whenever MIDD is highly suspected
(patients with monoclonal paraprotein and renal disorder
which cannot be explained by other causes). A BM biopsy
or aspirate, serum, and urine immunoelectrophoresis and
FLCs are needed for both diagnostic and response evalua-
tion purposes.
Treatment
Before the era of novel anti-myeloma agents, the overall
and renal prognosis was poor [72]. Data regarding the best
therapeutic approach remain limited; however, bortezomib-
based regimens are considered as a primary choice leading
to deep and rapid responses [76, 77]. Two retrospective
studies support the use of bortezomib-containing regimens
as ﬁrst line treatment with achievement of VGPR and
improved renal outcomes [71, 78]. Recent data [79] repor-
ted that patients with hematologic CR, achieved either with
ASCT or PI-based therapies, were more likely to achieve a
renal response, while baseline GFR < 20 mL/min/1.73 m2
and renal improvement, were identiﬁed as independent
predictors of progression to dialysis. Earlier diagnosis and
treatment initiation improve OS but not disease evolution to
end-stage renal disease (ESRD) [80]. Despite the high rates
of hematologic response with the bortezomib-based agents,
a signiﬁcant proportion of patients still progresses to ESRD.
The non-reversible renal impairment suggests that other
processes are involved in the pathogenesis induced by the
deposition of heavy and/or light fragments, and therefore
may become independent of the primary insult [76, 81]. The
therapeutic goal is to eradicate the monoclonal proteins and
stabilization or improvement of renal function; however, the
optimal combination, treatment duration, and salvage ther-
apeutic options remain to be further investigated. Triplet
combinations or the induction of an IMiD are reasonable,
although data regarding the role of IMiD are very limited
[71, 82].
Recommendations
Bortezomib-based regimens are considered as gold standard
for the treatment of MIDD both in frontline and relapsed/
refractory setting (1B). However, prospective randomized
trials are required to be performed to conﬁrm the available
data. ASCT/HDM should be considered for transplant-
eligible patients (1Β). Triplet combinations should be con-
sidered for relapsed/refractory patients (1C). The ther-




POEMS is a rare syndrome associated with an underlying
PC neoplasm. The acronym refers to the disease char-
acteristics: polyradiculoneuropathy, organomegaly, endo-
crinopathy, monoclonal plasma cell disorder, and skin
changes [83]. The major criteria to establish diagnosis are
polyradiculoneuropathy, clonal PC disorder, elevated vas-
cular endothelial growth factor (VEGF), sclerotic bone
lesions, and Castleman disease. Minor features include
endocrinopathy, organomegaly, characteristic skin changes,
papilledema, extravascular volume overload, and thrombo-
cytosis. The diagnosis of POEMS syndrome is made
with three major criteria, two of which (poly-
radiculoneuropathy and clonal PC disorder, almost always
λ) are mandatory, and at least one minor criterion (Sup-
plementary Table 2).
Recommendations
Perform iliac crest BM sampling or aspirate, abdomen and
pelvis CT scan, whole body X-rays and FDG-PET, pul-
monary function tests, heart U/S, endocrinal lab tests, serum
VEGF levels, serum and urine immunoﬁxation and FLCs to
evaluate the presence of major and minor POEMS criteria.
Treatment
The most effective therapeutic strategies target the under-
lying disorder rather than VEGF. Patients are distinguished
as those with no BM involvement and those with dis-
seminated disease. The approach differs for both groups.
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For the ﬁrst, radiation is the recommended treatment of
choice and improves both symptoms and prognosis: 35
patients were treated in a retrospective study only with
radiation with 97% 4-year OS and 52% 4-year failure-free
survival [84]. In a recent review both PFS and OS were
inferior for patients treated only with radiation, mainly
because these patients were sicker at the time of treatment
[85]. For patients with disseminated disease, radiation is not
curative, therefore systemic therapy is recommended. Large
bone lesions might require adjuvant radiation usually
6 months after chemotherapy. Unfortunately, there is a
signiﬁcant lag between successful therapy and neurologic
response. Maximum response is expected after 2–3 years.
Optimal response with FDG-PET may also lag by
6–12 months. No published randomized trials are available,
therefore therapeutic approaches are based on case series.
The ﬁrst prospective trial included 31 patients treated with
MDex with 81% hematologic response, 100% VEGF
response and 100% improvement of some grades in neu-
ropathy [86]. The French group treated 27 patients with
lenalidomide/dexamethasone (Rd) for two induction cycles
followed by high-dose therapy or radiation or for 9 cycles
followed by 12 cycles lenalidomide monotherapy
[NCT01639898, primary analysis]. The follow up is short,
however several patients responded neurologically and
rapidly, one patient however, progressed and one died.
Thalidomide and bortezomib should be used with cau-
tion due to increased risk of induced neuropathy [87–90].
High-dose chemotherapy with ASCT is also effective and
should be considered for young patients given the excellent
long-term results. Case series suggest that 100% of patients
achieve some neurologic improvement [85–87]. In a case
series of 59 patients, PFS was 98, 94, and 75% at 1, 2, and 5
years, respectively [86]. Other strategies (often used in case
reports or in very small patient cohorts) have been proposed
in the past, but their results are inferior or controversial.
Recommendations on POEMS therapeutic strategies are
listed in Table 5.
Recommendations
For patients with negative BM involvement by iliac crest
sampling, radiation is treatment of choice. For patients with
disseminated disease consider Rd or MDex (1A). Eligible
patients should undergo ASCT (1A). Bortezomib- and
thalidomide-based regimens should be avoided due to the
increased risk to deteriorate preexisting neuropathy (1B). In
the relapsed/refractory setting, retreatment with the avail-
able frontline agents is an option (1B).
Primary plasma cell leukemia (PPCL)
Diagnosis
PPCL is a rare and aggressive variant of MM, operationally
deﬁned by the presence of 20% and/or an absolute number
>2 × 10e9/L of clonal PC in the peripheral blood without a
previous history of MM [91–94]. PPCL should be con-
sidered a speciﬁc entity, distinguished from secondary PCL
(SPCL), which generally constitutes the leukemic evolution
of a pre-existing, end-stage relapsed/refractory MM, and
from extra-medullary myeloma that, by deﬁnition, excludes
peripheral blood dissemination.
PPCL is characterized by a higher prevalence of adverse
clinical and laboratory features as compared to MM [95]
(Supplementary Table 3) and an elevated genomic
instability, witnessed by an increased number of cytogenetic
aberrations and other molecular lesions at diagnosis
[95–97]. The prognosis of PPCL, though partially improved
as compared to previous decades after the introduction of
novel agents in clinical practice [98], remains unsatisfac-
tory, with a median OS of 1–2 years in elderly patients, and
about 3-years in patients undergoing stem cell transplants
[99–107]. Recently it was demonstrated in 482 newly
diagnosed patients with MM or plasma cell leukemia that
the presence of ≥5% circulating plasma cells in patients with
Table 5 Therapeutic choices for
POEMS syndrome
Therapeutic regimen Clinical outcomes
Radiation Improvement in 50–70% of patients
Corticosteroids 50% with clinical improvement
Melphalan-dexamethasone 81% with hematologic response, 100% with some neurologic
improvement
ASCT 100% with clinical improvement
Cyclophosphamide-dexamethasone 50% with clinical improvement
Lenalidomide-dexamethasone Majority of patients may respond
Thalidomide-dexamethasone Not recommended as 1rst-line due to induced neuropathy risk
Bortezomib-based regimen Almost all patients respond, consider neurotoxicity
Bevacizumab Will reduce VEGF levels, but several death reports
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myeloma at diagnosis has similar adverse prognostic impact
as plasma cell leukemia, indicating that probably a lower
cut-off for the deﬁnition of plasma cell leukemia should be
adapted in the future (107).
Recommendations
Diagnostic work-up and staging procedures in PPCL are
similar to those applied in MM; however, they have to be
implemented by peripheral blood analysis for measuring
circulating PC count and PET-CT for detecting possible
extra-medullary lesions [97].
Treatment
With some exception [108, 109], available data support the
use of bortezomib-based combinations as ﬁrst-line induc-
tion therapy for ﬁt patients [105, 110–112]. Aggressive
chemotherapy, combined with bortezomib ± thalidomide/
lenalidomide, such as hyper-CVAD-VD or VTD/VRD-
PACE may also be considered in younger patients, but there
is no clear evidence of their superiority [96].
Despite being less effective than in MM, high-dose
melphalan followed by ASCT is currently recommended in
all eligible PPCL patients who achieve a signiﬁcant
response after a brief course of induction treatment [95, 96,
99, 106, 113–118]. Of note, the best results have been so far
achieved when ASCT was integrated with the use of novel
agents [104, 105, 113]. Some data also suggest a possible
advantage of tandem-ASCT [111], but this has not been
conﬁrmed in a recent retrospective survey of EBMT [118].
Overall, though an allo-SCT with a myeloablative regi-
men may be potentially curative, the results so far obtained
upfront in PPCL do not show any survival advantage when
this procedure is compared to ASCT, being allo-SCT
associated with a lower relapse rate, but also with a much
higher risk of non-relapse-related mortality [118–120]. Pros
and cons of front-line allo-SCT should be therefore care-
fully discussed with eligible patients, who electively are
younger individuals with poor prognosis characteristics at
baseline, but who have achieved a good response to ﬁrst-
line induction treatment. In this setting, a sequence of
ASCT followed by allo-SCT, including reduced-intensity or
non-myeloablative regimens, has provided promising pre-
liminary data [118].
Results in patients not eligible for transplant procedures
because of age or frailty appear to be disappointing [95, 96,
99, 101, 112]. Likewise, current salvage therapies for
relapsed/refractory PPCL are rarely effective [95, 96, 101].
Therefore, patients with PPCL should always be considered
for enrolment in clinical trials [103]. Newer approaches
under investigation in MM [115], including various com-
binations of next generation PI/IMIDs and monoclonal
antibodies, CAR-T cells and novel target therapies, such as
selinexor (an inhibitor of nuclear exportin-1) or venetoclax
(a BCL-2 inhibitor, particularly active in presence of
t(11;14) [121], may emerge as possible future therapeutic
options also for PPCL patients.
Recommendations
There are no precise guidelines for the treatment of PPCL.
In particular, no randomized, phase III trials have been
performed in PPCL, while only two prospective, phase II
studies [104, 105] (Supplementary Table 4) have been
published so far.
Overall, current PPCL treatment should be immediate
and initially oriented toward a PI and IMID-based triplet as
induction, with short treatment-free intervals (1B). Preven-
tion of tumor lysis syndrome, bisphosphonates and anti-
infective prophylaxis are recommended in all patients.
Intrathecal prophylaxis should be also considered for
patients at high risk of CNS inﬁltration (i.e., those with a
high WBC count). Thromboprophylaxis should be given in
patients receiving IMIDs.
After induction phase, the treatment should ideally
include double ASCT, consolidation, and maintenance in all
eligible patients (1B). Frontline allo-SCT should be con-
sidered in selected cases (1B). The expert panel suggests
that aged, but still ﬁt patients not eligible for transplant
procedures, should be planned for continuous therapy,
ideally until response is maintained or signiﬁcant toxicities
occur. In very old and/or frail individuals, personalized
treatments (i.e. dose and time adjusted combinations of
lenalidomide or bortezomib plus dexamethasone) should be
given according to efﬁcacy and tolerability, aiming to
maintain patients on therapy as long as possible.
In relapsed/refractory PPCL a switch to drugs not used at
diagnosis should be considered, favouring combinations of
lenalidomide or pomalidomide plus dexamethasone with
carﬁlzomib or monoclonal antibodies (daratumumab or
elotuzumab) (expert consensus). Allo-SCT in relapsed and
eligible patients with sensitive disease after salvage treat-
ments is recommended (1B) A possible algorithm is illu-
strated in Fig. 1.
Conclusions
The treatment paradigm for PCDs has evolved over the past
few years resulting in substantial improvements in survival.
This trend is expected to continue with agents under
investigation for both newly diagnosed and relapsed or
refractory patients and combinations of them with the
existing regimens. The accurate and timely diagnosis along
with the emerging therapies expect to control the disease
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burden and improve the clinical outcomes. Despite the
rarity of these entities prospective, randomized trials should
be designed in order to identify the most beneﬁcial and
effective therapeutic approaches for these patients in need,
speciﬁcally those with AL-amyloidosis and plasma cell
leukemia.
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